Compare Cassava Sciences Inc (FLNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nasdaq Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Nasdaq Inc trades at $94.91 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 1112.3× Cassava Sciences Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NDAQ | |
|---|---|---|
Market Cap | $47.75M | $53.11B |
Sector | Health | Financials |
52-Week High | $4.64 | $100.98 |
52-Week Low | $0.87 | $76.85 |
Enterprise Value | -$34.93M | $59.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.
The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
